<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <title>Mallinckrodt / Endo – Timeline</title>
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta
    name="description"
    content="Chronological timeline of Mallinckrodt and Endo: opioid backdrop, bankruptcies, merger, and spin-off into Keenova and Par Health."
  />
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap" rel="stylesheet" />
  <link rel="stylesheet" href="style.css" />
</head>
<body>
<header>
  <div class="nav-inner">
    <div class="brand">
      <div class="brand-logo"></div>
      <div>
        <div class="brand-text-main">Keenova / Par Health</div>
        <div class="brand-text-sub">Timeline</div>
      </div>
    </div>
    <button class="nav-toggle" aria-label="Toggle navigation">
      <span></span>
      <span></span>
    </button>
    <nav class="nav-links">
      <a href="index.html">Overview</a>
      <a href="timeline.html">Timeline</a>
      <a href="litigation.html">Litigation</a>
      <a href="sources.html" class="nav-cta">Sources</a>
    </nav>
  </div>
</header>

<main class="page-shell">
  <section class="section">
    <div class="section-header">
      <div class="section-kicker">Chronology</div>
      <h2 class="section-title">Key events from 2016–2025</h2>
      <p class="section-subtitle">
        Dates and descriptions are drawn from bankruptcy documents, attorney general summaries, and financial/news reporting
        linked on the Sources page.
      </p>
    </div>

    <div class="section-body">
      <div class="timeline">
        <div class="timeline-item">
          <div class="timeline-dot"></div>
          <div class="timeline-label">
            Pre-bankruptcy settlement frameworks
            <span class="timeline-date">2016–2020</span>
          </div>
          <div class="timeline-body">
            State attorneys general such as those in California and North Carolina describe Mallinckrodt as a major generic
            opioid manufacturer. Around 2020, they outline a global settlement framework in which Mallinckrodt agrees to pay
            about $1.6&nbsp;billion in structured cash payments into opioid abatement trusts for states, local governments and
            tribes.<sup> (CA &amp; NC AGs)</sup>
          </div>
        </div>

        <div class="timeline-item">
          <div class="timeline-dot"></div>
          <div class="timeline-label">
            First Mallinckrodt Chapter 11 and MDT&nbsp;II
            <span class="timeline-date">Oct&nbsp;2020 – Jun&nbsp;2022</span>
          </div>
          <div class="timeline-body">
            Mallinckrodt files for Chapter&nbsp;11 in October&nbsp;2020, citing opioid litigation, Acthar-related disputes and a heavy
            debt load.<sup> (BioPharma Dive)</sup> A plan confirmed in early 2022 and effective June&nbsp;16&nbsp;2022 creates the Mallinckrodt
            Opioid Master Disbursement Trust&nbsp;II (MDT&nbsp;II), described on its website as a “hub” trust that receives settlement
            funds and distributes them to sub-trusts for states, tribes, hospitals and individuals.<sup> (MDT&nbsp;II, CA AG)</sup>
          </div>
        </div>

        <div class="timeline-item">
          <div class="timeline-dot"></div>
          <div class="timeline-label">
            Endo files for Chapter 11
            <span class="timeline-date">Aug&nbsp;2022</span>
          </div>
          <div class="timeline-body">
            Endo International files for Chapter&nbsp;11 in August&nbsp;2022 with roughly $8&nbsp;billion in debt.<sup> (Reuters)</sup> State AGs
            and the Endo Public Opioid Trust materials describe settlement structures that will allocate hundreds of millions of
            dollars to opioid abatement over time.<sup> (Endo Public Opioid Trust, CA AG)</sup>
          </div>
        </div>

        <div class="timeline-item">
          <div class="timeline-dot"></div>
          <div class="timeline-label">
            Second Mallinckrodt filing and revised deal
            <span class="timeline-date">Aug&nbsp;2023</span>
          </div>
          <div class="timeline-body">
            After emerging from its first Chapter&nbsp;11 and making an initial $450&nbsp;million payment to MDT&nbsp;II, Mallinckrodt
            misses a subsequent payment and files a second, pre-packaged Chapter&nbsp;11 case in August&nbsp;2023. The Washington Post
            and Reuters report that a new deal is negotiated to reduce the opioid settlement by nearly $1&nbsp;billion and to cut
            about $2&nbsp;billion in other debt, with existing equity cancelled.<sup> (Washington Post, Reuters, MDT&nbsp;II)</sup>
          </div>
        </div>

        <div class="timeline-item">
          <div class="timeline-dot"></div>
          <div class="timeline-label">
            Mallinckrodt plan confirmation and emergence
            <span class="timeline-date">Oct–Nov&nbsp;2023</span>
          </div>
          <div class="timeline-body">
            In October&nbsp;2023, a U.S. bankruptcy court approves Mallinckrodt’s second plan.<sup> (Reuters)</sup> Davis&nbsp;Polk’s summary
            notes that Mallinckrodt emerges from Chapter&nbsp;11 in November&nbsp;2023 with a capital structure consisting largely of
            “take-back” debt and equity held by first- and second-lien lenders.<sup> (Davis&nbsp;Polk)</sup>
          </div>
        </div>

        <div class="timeline-item">
          <div class="timeline-dot"></div>
          <div class="timeline-label">
            Endo’s plan approval and criminal resolution
            <span class="timeline-date">Mar&nbsp;2024</span>
          </div>
          <div class="timeline-body">
            Reuters reports that in March&nbsp;2024 a U.S. court approves Endo’s Chapter&nbsp;11 plan, which transfers more than 95% of
            the reorganized equity to lenders and dedicates around $600&nbsp;million to opioid and tax-related settlements.<sup> (Reuters)</sup>
            The Department of Justice separately announces over $1.5&nbsp;billion in criminal fines and forfeiture for misbranded
            Opana&nbsp;ER, alongside Endo’s contributions to the Endo Public Opioid Trust and other settlements.<sup> (DOJ, Endo Public Opioid Trust)</sup>
          </div>
        </div>

        <div class="timeline-item">
          <div class="timeline-dot"></div>
          <div class="timeline-label">
            Mallinckrodt–Endo merger announcement
            <span class="timeline-date">Mar&nbsp;13&nbsp;2025</span>
          </div>
          <div class="timeline-body">
            Financial Times and Reuters report that Mallinckrodt and Endo agree to merge in a nearly $7&nbsp;billion transaction.
            According to these outlets, Endo shareholders are slated to receive $80&nbsp;million in cash and about 49.9% of the
            combined company, with Mallinckrodt investors holding the remaining 50.1%, and the new group expects about
            $3.6&nbsp;billion in 2025 revenue and a NYSE listing.<sup> (FT, Reuters, MarketWatch, Investopedia)</sup>
          </div>
        </div>

        <div class="timeline-item">
          <div class="timeline-dot"></div>
          <div class="timeline-label">
            Merger closing
            <span class="timeline-date">Jul&nbsp;31&nbsp;2025</span>
          </div>
          <div class="timeline-body">
            Mallinckrodt’s corporate site states that on July&nbsp;31&nbsp;2025, Mallinckrodt and Endo “joined together to better serve
            patients and customers,” marking the closing of the merger.<sup> (Mallinckrodt.com)</sup> Industry commentary notes that the
            combined business spans specialty brands as well as a large generics and sterile injectables platform.<sup> (Pharmaphorum)</sup>
          </div>
        </div>

        <div class="timeline-item">
          <div class="timeline-dot"></div>
          <div class="timeline-label">
            Spin-off of Par Health and Keenova rebrand
            <span class="timeline-date">Nov&nbsp;2025</span>
          </div>
          <div class="timeline-body">
            Mallinckrodt’s site and media reports from Pharmaphorum, BioSpace and Fierce Pharma describe a subsequent separation
            in which the generics and sterile injectables business is spun off as Par Health and the remaining specialty
            therapeutics business adopts the Keenova Therapeutics name.<sup> (Mallinckrodt.com, Pharmaphorum, BioSpace, FiercePharma)</sup>
            Pharmaphorum reports that Keenova has pro forma 2024 sales of around $1.7&nbsp;billion and roughly 1,600 employees,
            while Par Health records quarterly sales of roughly $337&nbsp;million with around 4,000 employees.<sup> (Pharmaphorum, BioSpace)</sup>
          </div>
        </div>
      </div>
    </div>
  </section>

  <!-- SIMPLE TABLE -->
  <section class="section">
    <div class="section-header">
      <div class="section-kicker">Snapshot</div>
      <h2 class="section-title">High-level 2020–2025 summary</h2>
    </div>

    <div class="section-body">
      <div class="exhibit-label">Exhibit 1</div>
      <div class="exhibit-title">Selected milestones</div>
      <p class="exhibit-caption">
        Condensed view of the main events that frame the transaction story.<sup> (MDT&nbsp;II, AG materials, Reuters, FT, Mallinckrodt.com)</sup>
      </p>

      <table class="exhibit-table">
        <thead>
          <tr>
            <th>Year</th>
            <th>Company</th>
            <th>Event</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td>2020</td>
            <td>Mallinckrodt</td>
            <td>Files first Chapter&nbsp;11 amid opioid and Acthar-related exposures.</td>
          </tr>
          <tr>
            <td>2022</td>
            <td>Mallinckrodt</td>
            <td>Plan effective; MDT&nbsp;II trust created; settlement obligations structured over several years.</td>
          </tr>
          <tr>
            <td>2022</td>
            <td>Endo</td>
            <td>Files Chapter&nbsp;11 with about $8&nbsp;billion in debt and significant opioid exposure.</td>
          </tr>
          <tr>
            <td>2023</td>
            <td>Mallinckrodt</td>
            <td>Files second Chapter&nbsp;11; negotiates reduced opioid settlement and lower debt.</td>
          </tr>
          <tr>
            <td>2024</td>
            <td>Endo</td>
            <td>Plan approved; lenders receive &gt;95% of equity; substantial funds dedicated to the Endo Public Opioid Trust.</td>
          </tr>
          <tr>
            <td>2025</td>
            <td>Both</td>
            <td>Announce and close merger valued near $7&nbsp;billion; plan for NYSE listing and $3.6&nbsp;billion in 2025 revenue.</td>
          </tr>
          <tr>
            <td>2025</td>
            <td>Keenova / Par Health</td>
            <td>Spin-off of generics and injectables as Par Health; branded business rebranded as Keenova Therapeutics.</td>
          </tr>
        </tbody>
      </table>
    </div>
  </section>

  <section class="section" id="disclosure">
    <div class="disclosure">
      <p>
        <strong>Prepared by:</strong> Ted Nawrocki. This page summarizes information from public sources listed on the Sources
        page. It is informational only and should not be used as investment, legal, tax, accounting or medical advice.
      </p>
    </div>

    <footer>
      <div>© 2025 Ted Nawrocki. All rights reserved.</div>
      <div>All trademarks and company names are the property of their respective owners.</div>
    </footer>
  </section>
</main>

<script src="script.js"></script>
</body>
</html>
